In this new research study, PredicineCARE™ liquid biopsy next-generation sequencing assay assessed the correlations between circulating tumour DNA (ctDNA)-derived genomic markers and treatment response and survival outcome in Chinese patients with advanced breast cancer (ABC).
May 2022
In this new research study, PredicineATLAS™ (Assay B) liquid biopsy next-generation sequencing assay demonstrated superior performance compared to four other leading commercial liquid biopsy assays.
May 2022
In this study, the PredicineATLAS™ panel was used to detect germline variants in Chinese patients with advanced breast cancer.
April 2022
In this study, Predicine aimed to evaluate gemcitabine and cisplatin plus durvalub with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.
March 2022
This study evaluates circulating tumor DNA (ctDNA) in blood or urine, which can be used as biomarkers of PCa and the combination of these markers may increase the sensitivity and specificity of the detection of PCa.
March 2022
In this study, Predicine performed a retrospective analysis of seriallyprofled cell-free DNA (cfDNA) alterations in blood samples collected from mCRPC patients before and after starting chemotherapy who were followed for response and clinical outcomes.
March 2022
In this study, Predicine assessed the association between the poor prognostic 3-lipid signature (3LS), somatic genetic aberrations and clinical outcomes in mCRPC.
March 2022
Predicine’s cfDNA and cfRNA assays were utilized to assess the role of somatic alterations on treatment resistance in patients with metastatic castration-resistant prostate cancer.
October 2021
Utilizing the PredicineCARE™ assay, this study demonstrates that urinary tumor DNA (utDNA) outperformed circulating tumor DNA (ctDNA) from blood samples in identifying somatic alterations in patients with newly diagnosed urothelial bladder cancer.
September 2021
PredicineCARE™ liquid biopsy assay was utilized to evaluate the correlation between genomic alterations and progression-free survival in patients with hormone-receptor positive metastatic breast cancer in the US and China.
September 2021
In a study of patients with mCRPC, the PredicineCARE™ and PredicineRNA liquid biopsy assays were utilized to identify alterations that may be associated with a poorer prognosis. The study also demonstrated that serial testing of cfDNA offers the unique opportunity to predict benefit to therapy prior to the onset of biochemical or radiographic changes.
September 2021
The PredicineCARE™ liquid biopsy assay was utilized to identify PTEN, RB1 and TP53 copy number losses in plasma samples from patients with metastatic prostate cancer. These findings have profound clinical implications for a patient’s prognosis, treatment selection, and understanding subsequent resistance.
August 2021
了解更多信息Using PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.
May 2021
了解更多信息Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.
April 2021
了解更多信息PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.
April 2021
了解更多信息Using PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.
November 2020
了解更多信息Using PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.
November 2020
了解更多信息The first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.
May 2020
了解更多信息An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
May 2020
了解更多信息Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.
April 2020
了解更多信息Using Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.
February 2020
了解更多信息Validation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.
January 2020
了解更多信息The potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.
December 2019
了解更多信息• Results from the study, where PredicineCARE™ examine the feasibility and utility of plasma ctDNA detection in the diagnosis of invasive and non-organ-confined UTUC, presented at the 2022 annual conference at American Society of Clinical Oncology (ASCO).
June 2022
了解更多信息• Results from the study researching how age affects genomic alteration frequency, presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息• Results from the study examining the feasibility and utility of plasma ctDNA detection in the diagnosis of high risk and non-organ-confined UTUC, presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息• Results from the study investigating the molecular characteristics of DITT/NITT, presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息• Results from the study demonstrating a tumor-agnostic and actionable MRD assay (PredicineBEACON), developed with high sensitivity and capability to detect actionable mutations in blood-or urine-based circulating tumor DNA, presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息• Results from the study about how RJBLC-I2N003 is an investigator-initiated study to evaluate the clinical activity and predictive biomarkers for neoadjuvant immunotherapy with toripalimab (anti-PD-1) in muscle invasive bladder cancer (MIBC). presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息• Results from the study analyzing the prognostic significance of DDR alterations in mCRPC presented at the 2022 annual conference at American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU).
February 2022
了解更多信息•Results from the study utilizing a comprehensive next-generation sequencing (NGS) – based liquid biopsy to assess ctDNA mutation and copy number analysis to identify novel prognostic and predictive biomarkers were presented at the 2021 annual conference of the San Antonio Breast Cancer Conference (SABCS).
December 2021
了解更多信息•A multi-omics assay developed by Predicine was able to identify genome wide chromosomal changes, whole exome wide mutations, and whole genome wide methylation changes. Also, the whole genome wide methylation assay was able to distinguish prostate cancer patients from healthy donors.
October 2021
了解更多信息• Results from the study utilizing the PredicineCARE liquid biopsy assay to assess somatic alterations in women with different clinical subtypes of metastatic breast cancer were presented at the 2021 annual conference of the European Society of Medical Oncology (ESMO).
September 2021
了解更多信息•Results from the study utilizing the PredicineATLAS liquid biopsy assay to assess somatic alterations and tumor mutation burden in patients with metastatic urothelial carcinoma were presented at the annual conference of the European Society of Medical Oncology (ESMO).
September 2021
了解更多信息•Predictive value of germline ATM mutations in mPDAC patients receiving PD-L1 + CTLA4 combo immunotherapies, demonstrating the value of the PredicineATLAS test in both blood TMB profiling and germline profiling to identify patient subgroups who may benefit from immunotherapy.
June 2021
了解更多信息•Validation of Predicine’s tissue-agnostic MRD assay that detects cancer variants down to 0.005%.
April 2021
了解更多信息• Predicine’s LP-WGS assay for identification of segment-based CNVs and CNV abnormality in plasma samples from 500 cancer patients, including breast, prostate, pancreatic and lung cancers.
April 2021
了解更多信息• Predicine’s enzyme-controlled methylation assay demonstrates dramatic improvement over WGBS in reducing DNA damage and GC bias as well as increasing NGS reads mapping rate and mapping quality score.
April 2021
了解更多信息• Validation of PredcineCARE™’s ability to detect gene copy number loss (PTEN) in low fraction of tumor contents in plasma of prostate cancer patients.
April 2021
了解更多信息• Simultaneous profiling of Androgen Receptor splicing variants, hotspot mutations and amplifications at both cfDNA and cfRNA levels
February 2021
了解更多信息• Urine-based liquid biopsy treatment selection, disease monitoring, and early cancer detection in bladder cancer
February 2021
了解更多信息• Blood TMB towards personalized anti-PD-1 immunotherapy (toripalimab) in metastatic urothelial carcinoma
February 2021
了解更多信息• Blood-based detection of copy number variations (CNVs) in the PTEN-PI3K-AKT and AR pathway
• PTEN copy number loss
February 2021
了解更多信息• PredicineATLAS™ to assess germline mutations in breast cancer populations with different clinical features
• Large cohort study to support the development of precision oncology therapies for breast cancer patients
December 2020
了解更多信息• Calibration and validation of bTMB platforms to help harmonization between panels and laboratories thus improving the accuracy of testing to aid treatment decisions in oncology
• PredicineATLAS™ to assess bTMB
• Collaboration with AstraZeneca
November 2020
了解更多信息• ctDNA changes correlate with ORR in BTC patients treated with durvalumab + tremelimumab immunotherapy
• PredicineATLAS™ cfDNA
• Collaboration with AstraZeneca
May 2020
了解更多信息• ctDNA and cfRNA profiling, TMB
• Matched plasma and tissue
• Collaboration with Merck KGaA and EMD Serono
January 2020
了解更多信息• Methylation profiling in plasma cfDNA and urinary cfDNA
• PredicineMETHYLATION™
• Early cancer detection
June 2020
了解更多信息
• ctDNA profiling for AR mutation and amplification
• cfRNA profiling for AR-V7 splicing variants
• Therapy response and drug resistance
January 2020
了解更多信息• PTEN-PI3K, AR, DDR pathway alterations
• Mono- vs. bi-allelic gene deletion in BRCA, PTEN
• cfRNA-based detection of fusions and splice variants
January 2019
了解更多信息May 2022
February 2022
February 2022
February 2022
February 2022
February 2022
December 2021
December 2019
Pan Du, Eric Jia and Zhixin Zhao
December 2019
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
December 2019
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee
June 2019
了解更多信息Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad
April 2019
了解更多信息Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du
April 2019
了解更多信息Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu
February 2019
了解更多信息竭诚欢迎您前来洽谈业务合作！
请留下您的联系方式，我们会尽快与您沟通交流。